Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 468 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acne Vulgaris Clear all
Completed Phase 4 Interventional Results available

Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris

NCT01209949
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
16 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SkinPen Efficacy on Acne Scars on the Face and/or Back

NCT02646917
View directory record Official record
Conditions
Atrophic Acne Scar
Interventions
Aesthetic Microneedling Treatment
Procedure
Lead sponsor
Bellus Medical, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

NCT01498874
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Placebo, gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
17 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Hot Springs, Arkansas • Riverside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers

NCT01112787
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam, Vehicle Foam, Sodium Laural Sulfate, Distilled Water
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 2, 2026, 8:10 AM EDT
Active, not recruiting Early Phase 1 Interventional

Experience With Topical Acne Treatment

NCT05582434
View directory record Official record
Conditions
Acne
Interventions
clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel, adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel, Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 2, 2026, 8:10 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

An Investigation of a Multi-Function Skincare Product to Improve Aging, Eczema, and Acne Outcomes

NCT05873933
View directory record Official record
Conditions
Acne, Eczema, Skin Aging
Interventions
Hemptress Oil
Other
Lead sponsor
Hemptress
Industry
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Results available

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

NCT02052752
View directory record Official record
Conditions
Skin Diseases
Interventions
3% Benzoyl Peroxide, 3% Benzoyl Peroxide Placebo, Neutrogena Rapid Clear®
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

NCT03664752
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDP-120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
18
States / cities
Rogers, Arkansas • Manhattan Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)

NCT01038869
View directory record Official record
Conditions
Acne Vulgaris, Post Inflammatory Hyperpigmentation
Interventions
Azelaic acid
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Functional Usability and Feasibility Testing of the Profound Matrix™ System

NCT06192550
View directory record Official record
Conditions
Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic
Interventions
Profound Matrix™ System
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Marlborough, Massachusetts • New York, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris

NCT03128723
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Acne Mask
Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne

NCT00964223
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin and benzoyl peroxide gel (Duac® Topical Gel), benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Rockville, Maryland • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

NCT00689117
View directory record Official record
Conditions
Acne Vulgaris, Acne
Interventions
CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin), Vehicle Gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
1,649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 2, 2026, 8:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1450 Nm Laser

NCT00306371
View directory record Official record
Conditions
Acne, Acne Scars
Interventions
1450nm diode laser
Device
Lead sponsor
Skincare Physicians of Chestnut Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2006 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne

NCT02998671
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CJM112, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Culver City, California • Sacramento, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 2, 2026, 8:10 AM EDT
Recruiting Phase 4 Interventional

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

NCT07524946
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Bryant, Arkansas • Rogers, Arkansas • Freemont, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 2, 2026, 8:10 AM EDT
Not listed Not applicable Interventional

Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions

NCT05987319
View directory record Official record
Conditions
Wrinkle, Fine Lines, Crepey Skin, Acne Scars, Active Acne, Enlarged Pores, Stretch Mark, Loose Skin
Interventions
RadioFrequency Microneedling Device
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Westford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Not applicable Interventional

Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System

NCT00955461
View directory record Official record
Conditions
Photodamage, Irregular Pigmentation, Acne Scars
Interventions
RevLite laser treatment, Fractionated Laser treatment
Procedure
Lead sponsor
ConBio, a Cynosure Company
Industry
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris

NCT01773122
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone Formulation A, Dapsone Formulation B, Dapsone Formulation C, Dapsone 5% Gel
Drug
Lead sponsor
Allergan
Industry
Eligibility
16 Years to 35 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 2, 2026, 8:10 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Almond Supplementation on Mild to Moderate Acne

NCT05269641
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Food: whole almonds, Food: non-nut snack
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
15 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

NCT03852472
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Avacopan, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
91
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Not applicable Interventional Results available

Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring

NCT04606134
View directory record Official record
Conditions
Acne Scars - Mixed Atrophic and Hypertrophic
Interventions
Hybrid fractional laser, Alastin Regenerating Skin Nectar with TriHex Technology, Cetaphil face cream
Device · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

NCT03290027
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03, Placebo Comparator
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 2, 2026, 8:10 AM EDT